Palantir a high-risk investment with ’a one-of-a-kind growth and margin model’
Sheena Jonathan, co-founder and director at Natera, Inc. (NASDAQ:NTRA), recently sold shares worth approximately $914,873. The transactions, dated February 26, 2025, involved the sale of common stock at prices ranging from $155.66 to $162.64 per share. According to InvestingPro data, the company, currently valued at $20.48 billion, appears overvalued at current levels, though it has delivered an impressive 74% return over the past year.
The sales were made under a Rule 10b5-1 trading plan, a strategy that allows insiders to set up a predetermined plan to sell stocks. The transactions included shares held directly by Jonathan as well as shares held indirectly through Caraluna 1 Trust and Caraluna 2 Trust. InvestingPro analysis shows the company maintains a GOOD financial health score, with analysts setting a highest price target of $211.
Following these transactions, Jonathan retains ownership of 260,789 shares directly and additional shares through the trusts, totaling 43,282 shares. The sales were part of a series of planned transactions and do not necessarily indicate any change in the executive’s view of the company’s prospects.
In other recent news, Natera has reported its fourth-quarter 2024 earnings, surpassing Wall Street expectations with revenue reaching $476 million, a 53% increase year-over-year, and a narrower-than-anticipated loss per share of -$0.41. Despite this positive financial performance, Natera’s stock experienced a decline during regular trading hours. The company has also set its 2025 revenue guidance between $1.87 billion and $1.95 billion, indicating a 24% growth at the midpoint. Analyst firms TD Cowen and Canaccord Genuity have both maintained a Buy rating on Natera, with Canaccord Genuity raising its price target from $180 to $195 following the strong fourth-quarter results. TD Cowen highlighted the company’s promising 2025 guidance, which includes sales projections exceeding consensus estimates by approximately 5%. Additionally, Natera has achieved positive operating cash flows for the fourth consecutive quarter, showcasing consistent financial performance. The company’s strategic spending on operational expenses is expected to fuel further growth, despite higher costs impacting gross margin percentage. These developments reflect Natera’s robust growth levers, including increased test volumes and improved Medicare Advantage rates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.